FHTX financials
Foghorn Therapeutics (FHTX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
- FHTX revenue was $30.91M in fiscal 2025, net income -$74.28M.
FHTX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $30.91M | – | -$86.39M | -$74.28M | -1.18 |
| 2024 | $22.60M | – | -$102.68M | -$86.62M | -1.58 |
| 2023 | $34.16M | – | -$107.91M | -$98.43M | -2.34 |
| 2022 | $19.23M | – | -$117.14M | -$108.88M | -2.62 |
| 2021 | $1.32M | – | -$100.73M | -$101.32M | -2.73 |
| 2020 | $430.00K | – | -$68.53M | -$68.80M | -6.23 |